High-Dimensional Spatiotemporal Single-Cell and 3D Atlas of the Bone Marrow Microenvironment during Leukemic Progression
Preprint
Abstract
The bone marrow microenvironment (BMME) is essential for hematopoiesis and immunity, yet spatiotemporal single-cell analysis during leukemogenesis remains challenging. We characterized the BMME in femurs from wild-type and chronic myeloid leukemia (CML) mice at 7, 14 and 21 days post-induction by highly multiplexed and 3D microscopy. Using a 54-marker CODEX panel, we profiled 2,033,725 cells in 55 tissue regions of interest and identified 41 cell types through unsupervised clustering and supervised annotation. During leukemic progression, we observed an expansion of myeloid and progenitor cell populations, increased PD-L1 + leukemic cells, the upregulation of PD-1 on CD4 + and CD8 + T cells, and a profound loss of B cells, plasma cells and bone cells. Advanced CML exhibited a striking expansion of immature, pericyte-deficient vasculature that disrupted vascular niches and impaired hematopoietic stem/progenitor cell positioning. Spatial mapping revealed leukemia-specific cellular neighborhoods enriched in PD-1 + CD8 + T cells, suggesting localized immune cell exhaustion. Early-stage CML showed increaseds between plasmacytoid dendritic cells and megakaryocytes, whereas advanced CML featured heightened megakaryocyte emperipolesis of non-leukemic granulocytes. Megakaryocytes were morphologically irregular in CML mice and BM trephine biopsies from CML patients. Laser-capture microdissected megakaryocytes from newly diagnosed CML patients had reduced expression of cytoskeleton genes, which was reversed in advanced cases treated with tyrosine kinase inhibitors. 3D imaging revealed vascular disorganization and depleted megakaryocytes in the diaphysis, underscoring region-specific pathology. Together, this study provides a spatiotemporal single-cell atlas of the BMME during leukemic progression, showing how leukemic cells reprogram the niche to support their expansion and immune evasion.Keywords
Funding Information
- Medizinischen Fakultät, Eberhard Karls Universität Tübingen
- Institute of Pathology, University Hospital Tübingen
- State of Baden-Württemberg – Centers for Personalized Medicine Baden-Württemberg
- Mach-Gaensslen-Stiftung Schweiz
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P300PB_171189)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P400PM_183915)
- Lady Tata Memorial Trust
- Dres. Bayer-Foundation
- Swiss Cancer Research Foundation (KFS-5114-08-2020)
- European Commission (101116768)
- German Research Foundation (DFG), Cluster of Excellence iFIT ‘Image-Guided and Functionally Instructed Tumor Therapies’ (EXC 2180 - 390900677)
- German Research Foundation (DFG), Cluster of Excellence iFIT ‘Image-Guided and Functionally Instructed Tumor Therapies’ (INST 37/1228-1 FUGG)
- German Research Foundation (DFG), Cluster of Excellence iFIT ‘Image-Guided and Functionally Instructed Tumor Therapies’ (INST 37/1302-1 FUGG)
- German Research Foundation (DFG), Cluster of Excellence iFIT ‘Image-Guided and Functionally Instructed Tumor Therapies’ (INST 37/1310-1 FUGG)
- Brigitte und Dr. Konstanze Wegener-Stiftung
- Werner Jackstädt-Stiftung
- Bundesinstitut für Risikobewertung (60-0102-01.P641-12572660)
- Leukemia Research Foundation (1077776)
- China Scholarship Council (202108320058)
- China Scholarship Council (202108340026)
- IZKF Junior Research Group (2561-0-0)
- NIH (2U19AI057229-16)
- NIH (5P01HL10879707)
- NIH (5R01GM10983604)
- NIH (5R33CA18365403)
- NIH (5U01AI101984-07)
- NIH (5UH2AR06767604)
- NIH (5R01CA19665703)
- NIH (5U54CA20997103)
- NIH (5F99CA212231-02)
- NIH (1F32CA233203-01)
- NIH (5U01AI140498-02)
- NIH (1U54HG010426-01)
- NIH (5U19AI100627-07)
- NIH (1R01HL120724-01A1)
- NIH (R33CA183692)
- NIH (R01HL128173-04)
- NIH (5P01AI131374-02)
- NIH (5UG3DK114937-02)
- NIH (1U19AI135976-01)
- NIH (IDIQ17X149)
- NIH (1U2CCA233238-01)
- NIH (1U2CCA233195-01)
- DOD (W81XWH-14-1-0180)
- DOD (W81XWH-12-1-0591)
- Food and Drug Administration (HHSF223201610018C)
- Food and Drug Administration (DSTL/AGR/00980/01)
- Cancer Research UK (C27165/A29073)
- Bill and Melinda Gates Foundation (OPP1113682)
- Cancer Research Institute
- Parker Institute for Cancer Immunotherapy
- Kenneth Rainin Foundation (2018-575)
- Silicon Valley Community Foundation (2017-175329)
- Silicon Valley Community Foundation (2017-177799-5022)
- Beckman Center for Molecular and Genetic Medicine
- Juno Therapeutics (122401)
- Pfizer (123214)
- Celgene (133826)
- Celgene (134073)
- Vaxart (137364)
- Rachford & Carlotta A. Harris Endowed Chair
- DFG-funded NGS Competence Center Tübingen (INST 37/1049-1)
- Quantitative Biology Center (QBiC), University of Tübingen
This publication has 120 references indexed in Scilit:
- Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemiaNature Medicine, 2000
- Bone Marrow in Polycythemia Vera, Chronic Myelocytic Leukemia, and Myelofibrosis Has an Increased VascularityThe American Journal of Pathology, 2000
- Adhesion Molecule LFA-1/ICAM-1 Influences on LPS-induced Megakaryocytic Emperipolesis in the Rat Bone MarrowVeterinary Pathology, 1997
- BCR/ABL induces multiple abnormalities of cytoskeletal function.Journal of Clinical Investigation, 1997
- The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity [published erratum appears in J Cell Biol 1994 Mar;124(5):865]Journal of Cell Biology, 1994
- Expression of CD34 and platelet glycoproteins during human megakaryocytic differentiation.1992
- The frequency and significance of megakaryocytic emperipolesis in myeloproliferative and reactive statesAnnals of Hematology, 1992
- Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.Molecular and Cellular Biology, 1991
- The pericyte—A reviewTissue and Cell, 1986
- EMPERIPOLESIS OF GRANULOCYTES WITHIN MEGAKARYOCYTESBritish Journal of Haematology, 1985